ImmunoGen, Inc. Announces First Data For Its IMGN529 Product Candidate For Non-Hodgkin's Lymphoma

[Guest guest]

BlankImmunoGen, Inc. Announces First Data For Its IMGN529 Product Candidate For

Non-Hodgkin's Lymphoma

05 Apr 2011

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted

antibody-based anticancer products using its antibody expertise and Targeted

Antibody Payload (TAP) technology, today disclosed the profile and first

preclinical data for the Company's novel IMGN529 product candidate for the

treatment of B-cell malignancies including non-Hodgkin's lymphoma (NHL) and

chronic lymphocytic leukemia (CLL). This disclosure was made in conjunction with

the 102nd Annual Meeting of the American Association for Cancer Research (AACR)

taking place in Orlando, FL. IMGN529 consists of a CD37-targeting antibody that

has notable anticancer activity with the Company's potent cancer-cell killing

agent, DM1, attached using its SMCC linker.

" IMGN529 has a unique profile that we anticipate will make it particularly

effective for the treatment of NHL and other B-cell malignancies while also

providing favorable tolerability, " commented Lambert, Ph.D., Executive Vice

President and Chief Scientific Officer. " IMGN529 is on track to be the first

treatment for NHL that uses the tumor-killing power of our TAP with an antibody

having meaningful anticancer activity of its own. This product candidate has

demonstrated highly encouraging activity in preclinical testing and is on track

for IND submission this summer. "

Full story

http://mnt.to/l/3TcH